Intra-Cellular Therapies Nachrichten und Aktivitäten

Intra-Cellular Therapies ist einer der ...

• Russell 3000;
• TOB Iconic 10,000.

Intra-Cellular Therapies ist ein Unternehmen, das unter dem Börsenticker ITCI (US) gelistet ist.

Fusion, Akquisition und Finanzierung mit Intra-Cellular Therapies.

• Johnson & Johnson has announced the acquisition of Intra-Cellular Therapies  (veröffentlicht am 13, Januar 2025).

Siehe das Organigramm mit seine 15 wichtigsten Führungskräfte

Die meist gesuchten Biographien bei Intra-Cellular Therapies

• Sharon Mates, President, Chairman and Chief Executive Officer
• Rene Salas, Director
• Rory Riggs, Director

Eine Benachrichtigung erstellen
um Veränderungen bei Führungskräften von Intra-Cellular Therapies nachzuverfolgen.

Intra-Cellular Therapies hat 2.350 Konkurrenten , einschließlich Astellas Gene Therapies (USA), Eurofins (Luxemburg) und Lonza (Schweiz).

Popular M&A news in Biotechnologie

• Eli Lilly has announced the acquisition of Verve Therapeutics  (veröffentlicht am 17, Juni 2025).
• Sirius Therapeutics hat gerade eine Spendenaktion von 50 Millionen Dollar angekündigt. (veröffentlicht am 16, Juni 2025).
• BioNTech has announced the acquisition of CureVac  (veröffentlicht am 12, Juni 2025).

Andere vorgeschlagene Kontakte der Biotechnologie branche

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships bei WIRB-Copernicus Group
• Jasbir Seehra - Chief Executive Officer and Chairman of the Board bei Keros Therapeutics
• Deepika Verma - Associate Director of Data Science and Digitalization bei Wheeler Bio

Mehr über die Biotechnologie branche erfahren

Neueste Pressemitteilungen nach Intra-Cellular Therapies

• Intra-Cellular Therapies Settles CAPLYTA® (lumateperone) Patent Litigation with Sandoz | Intra-Cellular Therapies Inc.
• Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference | Intra-Cellular Therapies Inc.
• Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting | Intra-Cellular Therapies Inc.
• Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy | Intra-Cellular Therapies Inc.
• Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences | Intra-Cellular Therapies Inc.
• Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress | Intra-Cellular Therapies Inc.
• Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia | Intra-Cellular Therapies Inc.
• Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance | Intra-Cellular Therapies Inc.
• Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast | Intra-Cellular Therapies Inc.
• Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress | Intra-Cellular Therapies Inc.
• View more press releases Close

Social media about Intra-Cellular Therapies

• Intra-Cellular Therapies auf Wikipedia, Google News & Yahoo Finance
• Intra-Cellular Therapies auf LinkedIn, Twitter & YouTube